Research programme: allergen vaccines - Circassia

Drug Profile

Research programme: allergen vaccines - Circassia

Alternative Names: Allergen desensitisation - Circassia; Allergen immunotherapy - Circassia

Latest Information Update: 30 Jul 2012

Price : $50

At a glance

  • Originator Circassia
  • Class Epitopes; Subunit vaccines
  • Mechanism of Action Immunosuppressants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hypersensitivity

Most Recent Events

  • 30 Jul 2012 Preclinical development is ongoing for Hypersensitivity to birch pollen, & early research is ongoing for Hypersensitivity to Alternaria spp., Japanese cedar pollen & dog dander
  • 20 Jul 2010 Preclinical development is ongoing in United Kingdom
  • 25 Jan 2007 Preclinical trials in Allergy in United Kingdom (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top